Terms ending in 2032
Every in-force patent on Sandoz AG's record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,139,597 | Method for the Production of Ceftobiprole Medocaril In force · High confidence | Sandoz AG | In force | High confidence | |
| US 9,266,868 | Crystalline Form of Rivaroxaban Dihydrate In force · High confidence | Sandoz AG | In force | High confidence | |
| US 9,745,588 | Transcription Terminator Sequences In force · High confidence | Sandoz AG and Boehringer Ingelheim RCV GmbH & Co. KG | In force | High confidence | |
| US 9,458,146 | Crystalline Sodium Salt of an HIV Integrase Inhibitor In force · High confidence | Sandoz AG | In force | High confidence | |
| US 9,440,924 | Acetone Solvate of Ivabradine Hydrochloride In force · High confidence | Sandoz AG | In force | High confidence | |
| US 9,938,239 | Method For Preparing Silodosin In force · High confidence | Sandoz AG | In force | High confidence | |
| US 9,394,328 | Crystalline Dapagliflozin Hydrate In force · High confidence | Sandoz AG | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.